147 related articles for article (PubMed ID: 34952995)
1. Multicenter, randomized, double-blinded, placebo-controlled study of rabacfosadine in dogs with lymphoma.
Weishaar KM; Wright ZM; Rosenberg MP; Post GS; McDaniel JA; Clifford CA; Phillips BS; Bergman PJ; Randall EK; Avery AC; Thamm DH; Christman Hull AA; Gust CM; Donoghue AR
J Vet Intern Med; 2022 Jan; 36(1):215-226. PubMed ID: 34952995
[TBL] [Abstract][Full Text] [Related]
2. Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs.
Cawley JR; Wright ZM; Meleo K; Post GS; Clifford CA; Vickery KR; Vail DM; Bergman PJ; Thamm DH
J Vet Intern Med; 2020 Mar; 34(2):882-889. PubMed ID: 32064697
[TBL] [Abstract][Full Text] [Related]
3. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma.
Thamm DH; Vail DM; Post GS; Fan TM; Phillips BS; Axiak-Bechtel S; Elmslie RS; Klein MK; Ruslander DA
J Vet Intern Med; 2017 May; 31(3):872-878. PubMed ID: 28370378
[TBL] [Abstract][Full Text] [Related]
4. Alternating rabacfosadine and doxorubicin for treatment of naïve canine lymphoma.
Saba CF; Fan TM; Phillips BS; Wright ZM; Thamm DH
Vet Comp Oncol; 2024 Jun; 22(2):278-283. PubMed ID: 38616055
[TBL] [Abstract][Full Text] [Related]
5. Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials.
Saba CF; Clifford C; Burgess K; Phillips B; Vail D; Wright Z; Curran K; Fan T; Elmslie R; Post G; Thamm D
Vet Comp Oncol; 2020 Dec; 18(4):763-769. PubMed ID: 32346934
[TBL] [Abstract][Full Text] [Related]
6. Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses.
Saba CF; Vickery KR; Clifford CA; Burgess KE; Phillips B; Vail DM; Wright ZM; Morges MA; Fan TM; Thamm DH
Vet Comp Oncol; 2018 Mar; 16(1):E76-E82. PubMed ID: 28891260
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma.
Morges MA; Burton JH; Saba CF; Vail DM; Burgess KE; Thamm DH
J Vet Intern Med; 2014; 28(5):1569-74. PubMed ID: 25274443
[TBL] [Abstract][Full Text] [Related]
8. Tanovea® for the treatment of lymphoma in dogs.
De Clercq E
Biochem Pharmacol; 2018 Aug; 154():265-269. PubMed ID: 29778492
[TBL] [Abstract][Full Text] [Related]
9. Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 2014).
Lenz JA; Robat CS; Stein TJ
J Small Anim Pract; 2016 Aug; 57(8):429-34. PubMed ID: 27251593
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study.
Lori JC; Stein TJ; Thamm DH
Vet Comp Oncol; 2010 Sep; 8(3):188-95. PubMed ID: 20691026
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma.
Burton JH; Garrett-Mayer E; Thamm DH
Vet Comp Oncol; 2013 Dec; 11(4):306-15. PubMed ID: 22548975
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma.
Parsons-Doherty M; Poirier VJ; Monteith G
Can Vet J; 2014 Feb; 55(2):175-80. PubMed ID: 24489398
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma.
Saba CF; Hafeman SD; Vail DM; Thamm DH
J Vet Intern Med; 2009; 23(5):1058-63. PubMed ID: 19678892
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma.
Alvarez FJ; Kisseberth WC; Gallant SL; Couto CG
J Vet Intern Med; 2006; 20(5):1178-83. PubMed ID: 17063713
[TBL] [Abstract][Full Text] [Related]
15. Dacarbazine as single-agent therapy for relapsed lymphoma in dogs.
Griessmayr PC; Payne SE; Winter JE; Barber LG; Shofer FS
J Vet Intern Med; 2009; 23(6):1227-31. PubMed ID: 19709354
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol.
Curran K; Thamm DH
Vet Comp Oncol; 2016 Aug; 14 Suppl 1():147-55. PubMed ID: 26279153
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma.
Saba CF; Thamm DH; Vail DM
J Vet Intern Med; 2007; 21(1):127-32. PubMed ID: 17338160
[TBL] [Abstract][Full Text] [Related]
18. Asparaginase and MOPP treatment of dogs with lymphoma.
Brodsky EM; Maudlin GN; Lachowicz JL; Post GS
J Vet Intern Med; 2009; 23(3):578-84. PubMed ID: 19645842
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma.
Treggiari E; Elliott JW; Baines SJ; Blackwood L
Vet Comp Oncol; 2018 Jun; 16(2):194-201. PubMed ID: 28766920
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin.
Valerius KD; Ogilvie GK; Fettman MJ; Walton JA; Richardson K; Powers BE; McNiel EA; Rogers QR
J Am Vet Med Assoc; 1999 Feb; 214(3):353-6. PubMed ID: 10023395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
